G2 Quantix Solutions empowers biotech and pharma organizations to turn complex biological data into actionable insights—accelerating R&D and therapeutic innovation.
Founded by Gary Ge, Ph.D., a seasoned expert with over 15 years in computational drug discovery and development, G2 Quantix brings proven expertise in designing and scaling data and analytics platforms. Gary led the development of OmicSoft’s flagship products, including ArrayServer, a robust multi-omics data management system, and OncoLand and DiseaseLand, curated omics data solutions that power AI-driven drug discovery. These platforms are used by 15 of the top 20 global biopharma companies. His work at Amgen and Vor Bio spans the full R&D data lifecycle, supporting scientific operations and regulatory filings with both strategic planning and technical depth.
What We Do
Development of AI/ML Solutions
We develop predictive models powered by high-quality local data—like single-cell perturbation experiments and compound or antibody screening—to accelerate target discovery and drug development. Our approach leverages lab-in-the-loop AI grounded in advanced biological foundation models.
Research Informatics and Data Management
We design and customize cloud-native ELN, LIMS, and data lakes—making data AI-ready with insights from nearly a decade of Bio-IT experience across leading pharma and biotech organizations.
Computational Biology and Bioinformatics
Bioinformatics is essential to modern biotech. We build automated (event triggered), reproducible workflows for genomic analysis—freeing computational biologists from routine tasks to focus on in silico discovery and innovation.
Gene Editing Analysis
We support gene editing optimization and assay design (Cas9, Cas12a/Cpf1, ABE, and CBE), delivering FDA-ready data packages—backed by five years of experience in genotoxicity assessments (on-target, off-target, and translocation) and regulatory interactions for trem-cel, multiplexed editing, and allogeneic CAR-T programs.
Build Amazing Companies/Ventures
With experience from building OmicSoft (acquired by QIAGEN) and scaling Vor Bio, we support strategic decisions, from CRO evaluation, product development to fundraising, and can serve as interim CDO or Head of Computational Biology.